Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease

Table 5

Serological characteristics of systemic lupus erythematosus patients and healthy controls.

Autoantibody	Systemic lupus erythematosus patients; (%)	Healthy controls; (%)
Antinuclear antibodies IgG	73 (77.7%)	2 (7.4%)
Anti-double stranded DNA IgG	37 (39.4%)	0 (0.0%)
Anti-nucleosome IgG	30 (31.9%)	0 (0.0%)
Anti-Sm IgG	4 (4.3%)	0 (0.0%)
Anti-SS-A/Ro IgG	42 (44.7%)	0 (0.0%)
Anti-SS-B/La IgG	14 (14.9%)	0 (0.0%)
Anti-ribosomal P protein IgG	6 (6.4%)	0 (0.0%)
Anti-histone IgG	19 (20.2%)	0 (0.0%)
Anti-U1-RNP IgG	20 (21.3%)	0 (0.0%)
Anti-cardiolipin IgG	33 (35.1%)	0 (0.0%)
Anti-cardiolipin IgM	19 (20.2%)	1 (3.7%)
Anti-cardiolipin IgA	40 (42.6%)	1 (3.7%)
Anti-beta2-glycoprotein I IgG	7 (7.4%)	0 (0.0%)
Anti-beta2-glycoprotein I IgM	23 (24.5%)	1 (3.7%)
Anti-beta2-glycoprotein I IgA	23 (24.5%)	0 (0.0%)
Anti-oxidized low-density lipoprotein IgG	45 (47.9%)	0 (0.0%)
Anti-oxidized low-density lipoprotein IgM	68 (72.3%)	0 (0.0%)
Anti-prothrombin IgG	10 (10.6%)	0 (0.0%)
Anti-prothrombin IgM	12 (12.8%)	0 (0.0%)
Anti-prothrombin IgA	11 (11.7%)	0 (0.0%)
Anti-phosphatidylserine IgG	7 (7.4%)	0 (0.0%)
Anti-phosphatidylserine IgM	6 (6.4%)	1 (3.7%)
Anti-phosphatidylethanolamine IgG	12 (12.8%)	0 (0.0%)
Anti-phosphatidylethanolamine IgM	6 (6%)	0 (0.0%)
Lupus anticoagulant	15 (16.0%)	0 (0.0%)
Anti-neutrophil cytoplasmic antibodies IgG	39 (41.5%)	2 (7.4%)
Anti-proteinase 3 IgG	0 (0.0%)	0 (0.0%)
Anti-myeloperoxidase IgG	9 (9.6%)	0 (0.0%)
Anti-lactoferrin IgG	12 (12.8%)	0 (0.0%)
Anti-elastase IgG	9 (9.6%)	0 (0.0%)
Anti-BPI IgG	1 (1.1%)	0 (0.0%)
Anti-endothelial cell antibody IgG	42 (44.7%)	3 (11.1%)

BPI: bactericidal/permeability-increasing protein.